Study guide

5.3 Patient Counseling & Prospective Drug Utilization Review (DUR) Standards

Alabama MPJE Pharmacy Jurisprudence Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Board of Pharmacy Governance & Pharmacist Licensure

1.1 Alabama State Board of Pharmacy: Structure, Powers, Rulemaking & the 2026 Nine-Member Board 1.2 Pharmacist Licensure Requirements: Examination, Education, Background Check & Reciprocity 1.3 Pharmacy Interns, Externs & Preceptor Requirements: 1,500 Practical Hours & Supervision Standards

2 Chapter 2: Pharmacy Support Personnel, Ratios & Professional Standards

2.1 Pharmacy Technicians: Registration, Qualifications, Scope of Duties & Tiered Ratios 2.2 License Renewal Cycles, Continuing Education (CE) & Inactive Status 2.3 Disciplinary Grounds, Sanctions, Administrative Hearings & Impaired Pharmacist Rehabilitation

3 Chapter 3: Prescribing Authority, Practitioner Scopes & Corresponding Responsibility

3.1 Prescriptive Authority by Profession: Independent vs. Limited Scopes 3.2 Mid-Level Prescribing: PAs, CRNPs, CNMs, QACSC & Limited Purpose Schedule II Permits (LPSP) 3.3 Corresponding Responsibility, Legitimate Medical Purpose & Red Flags for Controlled Substance Diversion

4 Chapter 4: Opioids, Controlled Substance Clinical Safeguards & Naloxone Access

4.1 Opioid Prescribing Standards: ALBME Risk & Abuse Mitigation, MME Thresholds & Pain-Management Registration 4.2 Overdose Prevention: Statewide Naloxone Standing Order, Co-Prescribing & Pharmacist Dispensing Protocols 4.3 Alabama Prescription Drug Monitoring Program (PDMP): Dispenser Daily Reporting & Prescriber Query Mandates

5 Chapter 5: Clinical Services, Immunizations & Collaborative Practice

5.1 Pharmacist Immunization Authority, Protocols & Training Standards 5.2 Collaborative Drug Therapy Management (CDTM) & Collaborative Practice Agreements 5.3 Patient Counseling & Prospective Drug Utilization Review (DUR) Standards

6 Chapter 6: Prescription Validity, Electronic Prescribing & Security Standards

6.1 Prescription Form Validity: Written, Oral/Telephone & Facsimile Requirements 6.2 Electronic Prescribing & Electronic Prescriptions for Controlled Substances (EPCS) 6.3 Alabama Generic Drug Substitution: Two-Signature Line Law & Therapeutic Equivalence

7 Chapter 7: Prescription Processing, Labeling, Packaging & Emergency Dispensing

7.1 Prescription Labeling Standards & Expiration / Beyond-Use Dating 7.2 Federal Packaging Mandates: Poison Prevention Packaging Act (PPPA) & Child-Resistant Containers 7.3 Emergency Prescription Dispensing: 72-Hour Supply Rule & Disaster Provisions 7.4 Partial Filling of Prescriptions: Non-Controlled, Schedule II & Schedules III–V

8 Chapter 8: Prescription Transfers, Delivery & Remote Pharmacy Services

8.1 Prescription Transfer Rules: Non-Controlled vs. Controlled Substances 8.2 Prescription Delivery, Mail-Order Distribution & Out-of-State Permits 8.3 Patient Records, Confidentiality & Permitted Health Information Disclosures 8.4 Remote Pharmacist Work, Off-Site Order Entry & Off-Site Vaccine Order Processing

9 Chapter 9: Pharmacy Facility Standards, Security & Operational Supervision

9.1 Pharmacy Facility Permits: Application, Inspection, Renewal & Change of Ownership 9.2 Prescription Department Technical Equipment, References & Storage Standards 9.3 Pharmacy Security, Keys & Controlled Access Standards 9.4 Supervising Pharmacist Responsibilities & Temporary Absence

10 Chapter 10: Controlled Substances: Scheduling, Ordering, Inventory & Recordkeeping

10.1 Controlled Substance Scheduling: Federal Framework & Alabama State Variations 10.2 Controlled Substance Ordering & Procurement: DEA Form 222, CSOS & Invoicing 10.3 Controlled Substance Inventory Standards: Alabama Annual Inventory on January 15 10.4 Controlled Substance Records, 2-Year Retention & Filing Systems 10.5 Drug Distribution & Supply-Chain Security: DSCSA, Wholesale Distribution & Alabama Permits

11 Chapter 11: Controlled Substance Diversion Control, Disposal & Precursor Regulation

11.1 Theft and Loss of Controlled Substances: DEA Form 106 & Alabama Board Reporting Requirements 11.2 Controlled Substance Disposal, Destruction & Reverse Distribution 11.3 Ephedrine and Pseudoephedrine Sales Restrictions: Federal & Alabama Law 11.4 Non-Prescription Products: OTC Labeling, Repackaging, Exempt Narcotics & Restricted Distribution

12 Chapter 12: Compounding Standards, Institutional Practice & Medication Safety

12.1 Non-Sterile Compounding Standards: USP <795>, Beyond-Use Dating & Alabama Standards 12.2 Sterile Compounding & Hazardous Drug Handling: USP <797>, USP <800> & Facility Requirements 12.3 Institutional Pharmacy Practice: Absence of Pharmacist, Night Cabinets, Stat Cabinets & Emergency Kits 12.4 Medication Safety, Drug Recalls (Classes I-III), Adulteration, Misbranding & Return/Reuse Prohibitions

5.3 Patient Counseling & Prospective Drug Utilization Review (DUR) Standards

Key Takeaways Explain This Topic AI

Under Ala. Admin. Code r. 680-X-2-.21 and OBRA '90, a licensed pharmacist or a registered pharmacy intern under direct supervision must make a verbal, face-to-face offer to counsel on all new prescriptions when the patient or caregiver is present.

For mail-order, delivery, or remote dispensing, the pharmacy must provide written notice offering counseling and include a printed statement containing a toll-free or local telephone number providing direct access to a pharmacist.

Alabama law explicitly requires a printed statement containing the pharmacy's telephone number on every prescription label or auxiliary container to facilitate patient contact.

Only pharmacists and interns may counsel or explain medications; supportive personnel (technicians and cashiers) may only ask the preliminary question regarding counseling and cannot answer clinical questions.

Prospective Drug Utilization Review (DUR) is mandatory prior to dispensing any prescription order (new or refill), requiring pharmacists to screen for over/under-utilization, therapeutic duplication, interactions, incorrect dosage/duration, and misuse.

Last updated: September 2026

5.3 Patient Counseling & Prospective Drug Utilization Review (DUR) Standards

Note

Statutory & Regulatory Foundation : Patient counseling and prospective Drug Utilization Review (DUR) in Alabama are governed by Ala. Admin. Code r. 680-X-2-.21 ( Pharmacists and Pharmacies Offer to Counsel ), the Alabama Pharmacy Practice Act ( Ala. Code § 34-23-1 et seq. ), and the federal mandates of the Omnibus Budget Reconciliation Act of 1990 (OBRA '90) ( 42 U.S.C. § 1396r-8(g) ). While OBRA '90 established federal counseling standards for Medicaid beneficiaries, Alabama law broadens this mandate to cover all patients receiving outpatient prescription medications , regardless of payment source.

The final point of contact between a healthcare professional and an outpatient receiving medication occurs at the pharmacy prescription counter. To protect the public from preventable medication errors, adverse drug reactions, and treatment failures, Alabama law imposes strict, non-delegable duties on licensed pharmacists to evaluate the clinical safety of every prescription order prior to dispensing (prospective DUR) and to ensure that an oral offer to counsel is personally extended to the patient or caregiver. On the Multistate Pharmacy Jurisprudence Examination (MPJE), candidates must demonstrate precise knowledge regarding when counseling is mandatory versus discretionary, the methods of delivering the offer across various dispensing channels, the strict exclusion of supportive personnel from clinical communication, patient waiver requirements, and the specific screening criteria comprising prospective DUR.

1. The Patient Counseling Mandate: Origins & Core Requirements

Under Ala. Admin. Code r. 680-X-2-.21 , an affirmative legal obligation is placed on the pharmacy and the dispensing pharmacist to facilitate direct patient-pharmacist communication.

Mandatory Offer on All New Prescriptions

Alabama law establishes a clear distinction between new prescriptions and refill orders:

All New Prescriptions : An oral, face-to-face offer to counsel must be made on every new prescription order presented to the pharmacy. A "new prescription" is defined as any medication not previously dispensed to the patient by the pharmacy, or a previously dispensed medication that has undergone a change in dosage form, strength, dose, route, or administration directions.

Refill Prescriptions : On refill prescriptions, counseling is not universally mandatory on every single transaction; rather, the pharmacist must offer or provide counseling when deemed appropriate in the pharmacist's professional judgment . Situations demanding refill counseling include: significant gaps in adherence, early refill attempts, suspected adverse reactions, potential drug interactions resulting from newly co-prescribed therapy, or whenever the patient or caregiver requests clinical clarification.

In-Person Face-to-Face Standard

When a patient or caregiver is physically present in the pharmacy to collect a new prescription, the offer to counsel must be delivered verbally and in person . Handing the patient a pre-printed informational leaflet or directing the patient to read an electronic credit card terminal prompt does not satisfy the statutory requirement for an oral offer. The offer must be an active, interpersonal communication. +-----------------------------------------------------------------------------------------+

  • | PATIENT COUNSELING MANDATE SUMMARY |
  • +-----------------------+-----------------------------------------------------------------+
  • | Prescription Type | Legal Standard under Ala. Admin. Code r. 680-X-2-.21 |
  • +-----------------------+-----------------------------------------------------------------+
  • | New Prescription | MANDATORY oral, face-to-face offer to counsel by pharmacist |
  • | (or modified order) | or supervised pharmacy intern. |
  • +-----------------------+-----------------------------------------------------------------+
  • | Refill Prescription | Required when deemed appropriate in the pharmacist's |
  • | | professional judgment, or upon patient/caregiver request. |
  • +-----------------------+-----------------------------------------------------------------+
  • | Delivered / Mailed | Written offer accompanying shipment + printed statement with |
  • | Prescriptions | toll-free or local telephone number providing pharmacist access.|
  • +-----------------------+-----------------------------------------------------------------+
  • 2. Remote Dispensing: Delivery, Mail-Order & Mandatory Telephone Statement

When prescriptions are dispensed outside traditional face-to-face community retail transactions—such as through pharmacy delivery couriers, mail-order pharmacies, institutional outpatient services, or specialty delivery networks—the physical absence of the patient necessitates alternative statutory compliance mechanisms.

Delivery & Mail-Order Protocol

Under Ala. Admin. Code r. 680-X-2-.21 , if the medication is delivered to the patient's residence or shipped via postal carrier, the pharmacy must satisfy two co-equal statutory duties:

Written Offer to Counsel : Provide written communication accompanying the delivered prescription clearly informing the patient of their right to receive clinical medication counseling;

Toll-Free or Local Telephone Access : Include a printed statement providing a toll-free telephone number (for pharmacies servicing patients outside their local calling area) or a local telephone number (for local delivery networks). The telephone line must be operational during normal business hours to allow direct, uninhibited telephonic access to a licensed pharmacist.

The Mandatory Telephone Number Printed Statement on Labels

In addition to delivery-specific notices, Alabama pharmacy statutes explicitly mandate that every prescription label or auxiliary container dispensed in the state must display a printed statement containing the pharmacy's telephone number . This requirement guarantees that regardless of how or where the prescription was picked up or delivered, the patient possesses immediate printed access to the pharmacy's contact information to seek professional advice regarding adverse reactions, administration questions, or emergency issues.

3. Personnel Authorized to Counsel: Strict Professional Boundaries

A central focus of ALBOP regulatory enforcement and MPJE examination items is the strict limitation of counseling authority to professional personnel .

Authorized Personnel

Under Alabama law, ONLY the following individuals may legally provide patient counseling or clinical explanations regarding prescription or over-the-counter medications:

Licensed Pharmacist : An individual holding an active, unrestricted license issued by ALBOP.

Registered Pharmacy Intern : A pharmacy student or graduate registered with ALBOP who provides counseling under the direct and immediate supervision of a licensed pharmacist. The preceptor remains legally responsible for the accuracy and completeness of the intern's counseling.

The Role of Supportive Personnel (Technicians & Cashiers)

Supportive personnel—including registered pharmacy technicians, certified pharmacy technicians, cashiers, delivery drivers, and clerks—are strictly prohibited from counseling patients, explaining drug indications, discussing potential adverse effects, or interpreting prescriber directions .

Permissible Administrative Interaction : A technician or cashier operating a pick-up register may ask the preliminary administrative question: "Would you like to speak with the pharmacist regarding your medication?"

Impermissible Delegation : If a patient responds affirmatively to the technician's question, or if the patient asks any question regarding the medication (such as "Can I take this with food?" or "Why did the doctor change the color of these pills?" ), the technician must immediately stop the transaction and summon the pharmacist . A technician who attempts to answer the question, or who advises the patient based on their own personal knowledge or packaging labels, commits an unlawful practice of pharmacy under Ala. Code § 34-23-33 .

Warning

Critical MPJE Distinction — Solicited Refusals : A common exam scenario involves a cashier or technician saying, "You don't have any questions on this, do you? Sign here." This practice is illegal in Alabama. An offer made by a non-pharmacist that discourages counseling or prompts a refusal without a genuine opportunity to consult a pharmacist violates Ala. Admin. Code r. 680-X-2-.21 .

4. Scope and Elements of Patient Counseling

When counseling is provided, it must be comprehensive and tailored to the patient's individual clinical profile. Under Ala. Admin. Code r. 680-X-2-.21 and OBRA '90 standards, the pharmacist should discuss the following eight (8) core clinical elements when deemed clinically significant in the pharmacist's professional judgment:

Name and Description of Medication : Brand name, generic chemical name, and therapeutic class;

Dosage Form, Dose, Route & Duration : Specific formulation (e.g., extended-release vs. immediate-release), prescribed dosage, route of administration, and intended duration of therapy;

Special Directions & Precautions : Proper preparation (e.g., shaking suspensions), administration techniques (e.g., inhalers, eye drops, subcutaneous pens), and dietary precautions (e.g., taking with food, avoiding alcohol or grapefruit juice);

Common Severe Adverse Effects & Contraindications : Clinically significant side effects, adverse drug interactions, therapeutic contraindications, and specific actions required if severe reactions occur;

Techniques for Self-Monitoring : Patient self-monitoring parameters (e.g., blood pressure logs, peak flow monitoring, daily weights for heart failure, home blood glucose tracking);

Proper Storage Conditions : Specific storage requirements (e.g., refrigeration at 2°C to 8°C, protection from freezing, light-resistant containers, keeping away from bathroom humidity);

Prescription Refill Information : Authorized refill count, expiration date of refills, and refill reordering procedures; and

Action in Event of a Missed Dose : Concrete instructions on what to do if a dose is missed (e.g., whether to take immediately, skip if near the next scheduled dose, and never doubling up doses).

Patient Refusal & Documentation Mandate

Alabama law explicitly recognizes that a patient or caregiver possesses the absolute legal right to decline counseling. A pharmacist cannot force clinical instruction upon an unwilling patient. However, to protect public safety and preserve regulatory compliance:

Documentation of Refusal : Whenever a patient or caregiver refuses an offer to counsel, the pharmacist must document the refusal in the pharmacy's dispensing records (via electronic signature log, electronic pharmacy management software, or a written log book);

Auditing Compliance : During unannounced ALBOP inspections, Board investigators review dispensing records for counseling documentation. A high-volume pharmacy demonstrating a statistical pattern of 100% counseling refusals will face heightened inspectorial scrutiny for improper technician-solicited waivers.

5. Prospective Drug Utilization Review (DUR) Standards

Under Ala. Admin. Code r. 680-X-2-.21 and OBRA '90, patient counseling is the outward communication resulting from an inward clinical evaluation called Prospective Drug Utilization Review (DUR) .

Mandatory Timing

Prospective DUR is an affirmative clinical duty that must be performed prior to dispensing any prescription order (new or refill) . The dispensing pharmacist must examine the patient profile and all available clinical history to identify therapeutic problems before the drug leaves the prescription department.

The Seven (7) Core Prospective DUR Screening Criteria

The pharmacist must systematically screen each prescription against the following seven clinical criteria: +-----------------------------------------------------------------------------------------+

  • | PROSPECTIVE DUR CORE SCREENING CRITERIA |
  • +-----------------------------------+-----------------------------------------------------+
  • | Screening Category | Clinical Focus & Risk Evaluated |
  • +-----------------------------------+-----------------------------------------------------+
  • | 1. Over-Utilization or | Excessive dosing, early refill requests indicating |
  • | Under-Utilization | misuse/diversion, or poor adherence leading to gaps.|
  • +-----------------------------------+-----------------------------------------------------+
  • | 2. Therapeutic Duplication | Concurrent use of two or more drugs from the same |
  • | | chemical class or pharmacological mechanism. |
  • +-----------------------------------+-----------------------------------------------------+
  • | 3. Drug-Disease Contraindications | Prescriptions that exacerbate an underlying disease |
  • | | (e.g., beta-blockers in severe asthma, NSAIDs in CKD|
  • +-----------------------------------+-----------------------------------------------------+
  • | 4. Drug-Drug Interactions | Clinically significant pharmacokinetic or dynamic |
  • | | interactions (e.g., warfarin + amiodarone). |
  • +-----------------------------------+-----------------------------------------------------+
  • | 5. Incorrect Dose or Duration | Doses exceeding safe limits, improper pediatric wt |
  • | | dosing, or incorrect antibiotic durations. |
  • +-----------------------------------+-----------------------------------------------------+
  • | 6. Drug-Allergy Interactions | Known hypersensitivity reactions or cross- |
  • | | reactivity (e.g., penicillin allergy + cephalosporin|
  • +-----------------------------------+-----------------------------------------------------+
  • | 7. Clinical Abuse or Misuse | Aberrant fill patterns, poly-prescriber behavior, or|
  • | | signs of diversion under Alabama controlled laws. |
  • +-----------------------------------+-----------------------------------------------------+
  • Professional Duty to Intervene & Resolve Alerts

Prospective DUR is not a passive mechanical exercise. When a computer dispensing system generates a severe DUR alert (such as a major drug interaction or severe duplicate therapy):

The pharmacist cannot blindly override the warning screen without clinical evaluation;

The pharmacist has an affirmative legal duty to investigate the conflict, review the clinical context, and, if necessary, contact the prescriber to clarify or modify the order;

If the pharmacist determines in their professional judgment that dispensing is safe (e.g., the prescriber intentionally co-prescribed medications with planned monitoring), the pharmacist must document the clinical rationale and resolution in the dispensing system;

Overriding a severe, black-box interaction without clinical justification that subsequently results in patient harm constitutes professional negligence and grounds for license suspension under Ala. Code § 34-23-33 .